Back to Results

Sophia Genetics SA (SOPH)

Sophia Genetics SA is a healthcare technology company listed on NASDAQ as common stock. The company develops cloud-native software for the healthcare sector, centered on its SOPHiA DDM platform, which is designed to analyze multimodal data sets and generate diagnostic insights. Its software and related applications are used by hospitals, laboratories, and biopharmaceutical companies. Sophia Genetics serves these customers through a direct sales force as well as distributors and industry collaborators across Switzerland, France, Italy, the rest of Europe, North America, the United States, Latin America, and the Asia-Pacific region. Incorporated in 2011, the company is based in Rolle, Switzerland.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-SOPH
$5.95
-27.3% Downside
Overvalued
$9.75
19.0% Upside
Undervalued
Fair
0.0%
November 10, 2026
8.4x
8.1x
698.9 M
651.4 M
7.8%
76.8%
-6.8
51.0%
Valuation • Fair Value

Sophia Genetics SA (NASDAQ-SOPH) Fair Value by Valuation Model

Review the available estimates for Sophia Genetics SA (NASDAQ-SOPH), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$5.95

Estimated downside of 27.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$6.23

Discounted cash flow valuation reference.

Comps Fair Value

$5.68

Comparable-company valuation reference.

Analyst Price Target

$9.75

Analysts imply upside of 19.0%.

How to read these valuation models

Use the 5 available valuation references for Sophia Genetics SA (NASDAQ-SOPH) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Sophia Genetics SA (NASDAQ-SOPH)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

86.167 M

Current operating scale indicator.

Revenue Forecast

95.1 M

Forward revenue estimate.

EBITDA

-71.746 M

Current operating profitability reference.

EBITDA Forecast

-31.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Sophia Genetics SA (NASDAQ-SOPH) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Sophia Genetics SA (NASDAQ-SOPH)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-3.10

No elevated caution signal from this screen.

Altman Z-Score

-6.8

Lower score that deserves closer risk review.

FCF / Net Income

51.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Sophia Genetics SA (NASDAQ-SOPH). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Sophia Genetics SA (NASDAQ-SOPH)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 10, 2026

Days to Earnings

53

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Sophia Genetics SA (NASDAQ-SOPH), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Sophia Genetics SA (NASDAQ-SOPH) Stock Forecast & Technical Outlook

Review Sophia Genetics SA (NASDAQ-SOPH) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Sophia Genetics SA (NASDAQ-SOPH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Sophia Genetics SA (NASDAQ-SOPH) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Sophia Genetics SA (NASDAQ-SOPH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Sophia Genetics SA (NASDAQ-SOPH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Sophia Genetics SA (NASDAQ-SOPH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Sophia Genetics SA (NASDAQ-SOPH)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Sophia Genetics SA (NASDAQ-SOPH) has a Strong Buy consensus, with 5 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 5
Hold 0
Sell 0
FAQ • Fast Investor Answers

Sophia Genetics SA (NASDAQ-SOPH) Stock FAQ

Data-supported answers about Sophia Genetics SA (NASDAQ-SOPH), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$5.95
Estimated downside 27.3%
Valuation Rating
Overvalued
Estimated downside of 27.3%
Analyst Target
$9.75
Implied upside 19.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Sophia Genetics SA (NASDAQ-SOPH) is $5.95. This implies an estimated downside of 27.3% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 27.3% versus the current market price.

The available analyst price target for Sophia Genetics SA (NASDAQ-SOPH) is $9.75. The analyst target implies estimated upside of 19.0%.

The current financial health read for Sophia Genetics SA (NASDAQ-SOPH) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Sophia Genetics SA (NASDAQ-SOPH) is November 10, 2026.

The latest available data indicates no current dividend yield for Sophia Genetics SA (NASDAQ-SOPH).

The current market capitalization listed for Sophia Genetics SA is 698.9 M.

The current enterprise value listed for Sophia Genetics SA is 651.4 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Sophia Genetics SA is NASDAQ-SOPH, and the stock is listed on NASDAQ.

Sophia Genetics SA (NASDAQ-SOPH) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Sophia Genetics SA is 7.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Sophia Genetics SA is 76.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Health Care Technology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

VEEV NYSE Veeva Systems Inc Class A Fair Value Fair Market Cap 42.13 B
WAY NASDAQ Waystar Holding Corp Fair Value Undervalued Market Cap 4.92 B
DOCS NYSE Doximity Inc Fair Value Undervalued Market Cap 4.654 B
HTFL NASDAQ Heartflow Inc Fair Value Overvalued Market Cap 4.413 B
SDGR NASDAQ Schrodinger Inc Fair Value Overvalued Market Cap 2.171 B
CERT NASDAQ Certara Inc Fair Value Undervalued Market Cap 1.284 B
GDRX NASDAQ Goodrx Holdings Inc Fair Value Undervalued Market Cap 1.153 B
TDOC NYSE Teladoc Inc Fair Value Undervalued Market Cap 1.145 B
HSTM NASDAQ HealthStream Inc Fair Value Fair Market Cap 893.1 M
PHR NYSE Phreesia Inc Fair Value Undervalued Market Cap 623.2 M
CTEV NYSE Claritev Corp Fair Value Fair Market Cap 522.2 M
EVH NYSE Evolent Health Inc Fair Value Undervalued Market Cap 417.2 M
SLP NASDAQ Simulations Plus Inc Fair Value Undervalued Market Cap 372.9 M
AMWL NYSE American Well Corp Fair Value Fair Market Cap 233.9 M
LFMD NASDAQ LifeMD Inc Fair Value Undervalued Market Cap 155.4 M
DH NASDAQ Definitive Healthcare Corp Fair Value Bargain Market Cap 138.8 M
OPRX NASDAQ OPTIMIZERx Corp Fair Value Bargain Market Cap 136.7 M
HCAT NASDAQ Health Catalyst Inc Fair Value Fair Market Cap 134 M
CCLD NASDAQ CareCloud Inc Fair Value Fair Market Cap 91.787 M
DRIO NASDAQ DarioHealth Corp Fair Value Overvalued Market Cap 70.556 M